The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity to warfarin therapy

Thrombosis Research

Volumn 115, Issue 3, 2005, Pages 199-203

  Pchelina, Sofya N ^a,b   Sirotkina, Olga V ^b   Taraskina, Anastasiya E ^b   Vavilova, Tatyana V ^a   Shwarzman, Alexander L ^b   Schwartz, Eugene I ^a,b  

^a PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^b PETERSBURG NUCLEAR PHYSICS INSTITUTE   (Russian Federation)

Author keywords

CYP2C9 polymorphism; Oral anticoagulants; Pharmacogenetics; Warfarin therapy

Indexed keywords

CYTOCHROME P450 2C9; GENOMIC DNA; WARFARIN;

ADOLESCENT; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING DISORDER; CONTROLLED STUDY; DNA DETERMINATION; DRUG MONITORING; DRUG SENSITIVITY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; SAMPLE SIZE; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENETICS, POPULATION; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREVALENCE; RUSSIA; THROMBOSIS; URBAN POPULATION; VARIATION (GENETICS); WARFARIN;

EID: 11144343361     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.08.020     Document Type: Article

References (14)

1. J. Hirsh, V. Fuster, J.L. Ansell, and J.L. Halperin American Heart Association/American College of Cardiology foundation guide to warfarin therapy Circulation 107 2003 1692 1711
2. J.O. Miners, and D.J. Birkett Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism Br. J. Clin. Pharmacol. 45 1998 525 536
3. M.K. Higashi, D.L. Veenstra, L.M. Kondo, A.K. Wittkowsky, S.L. Srinonanprachanh, and F.M. Farin Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy JAMA 287 2002 1690 1698
4. A.R. Tabrizi, B.A. Zehnbauer, I.B. Borecki, S.D. McGrath, T.G. Buchman, and B.D. Freeman The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin J. Am. Coll. Surg. 194 2002 267 273
5. D. Tassies, C. Freire, J. Puoan, S. Maragall, J. Monteagudo, and A. Ordinas Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation Haematologica 87 2002 1185 1191
6. C.R. Lee, J.A. Goldstein, and J.A. Pieper Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data Pharmacogenetics 12 2002 251 263
7. P.S. Wells, A.M. Holbrook, N.R. Crowther, and J. Hirsh Interactions of warfarin with drugs and food Ann. Intern. Med. 121 1994 767 783
8. J. Sambrook, E.F. Fritsch, and T. Maniatis Molecular cloning: a laboratory manual 1989 Cold Spring Harbor Laboratory Press Cold Spring Harbor (NY)
9. U. Yasar, E. Eliasson, M.L. Dahl, I. Johansson, M. Ingelman-Sundberg, and F. Sjoqvist Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population Biochem. Biophys. Res. Commun. 254 1999 628 631
10. H. Takahashi, and H. Echizen Pharmacogenetics of warfarin elimination and its clinical implications Clin. Pharmacokinet. 40 2001 587 603
11. A.K. Daly, and B.P. King Pharmacogenetics of oral anticoagulants Pharmacogenetics 13 5 2003 247 252
12. J. Taube, D. Halsall, and T. Baglin Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment Blood 96 2000 1816 1819
13. D.J. Seward, R.L. Haining, K.R. Henne, G. Davis, T.H. Rushmore, and W.F. Trager Genetic association between sensitivity to warfarin and expression of CYP2C9*3 Pharmacogenetics 7 5 1997 361 367
14. F. Peyvandi, M. Spreafico, S.M. Siboni, M. Moia, and P.M. Mannucci CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy Clin. Pharmacol. Ther. 75 3 2004 198 203